Pregabalin Doesn't Cut Intensity of Sciatica-Linked Leg Pain

Share this content:
Pregabalin Doesn't Cut Intensity of Sciatica-Linked Leg Pain
Pregabalin Doesn't Cut Intensity of Sciatica-Linked Leg Pain

WEDNESDAY, March 22, 2017 (HealthDay News) -- Pregabalin does not significantly reduce the intensity of leg pain associated with sciatica, according to a study published in the March 23 issue of the New England Journal of Medicine.

Stephanie Mathieson, from the University of Sydney, and colleagues conducted a randomized trial of pregabalin in patients with sciatica. Two hundred nine patients were randomized to receive either pregabalin at a dose of 150 mg per day, which was adjusted to a maximum of 600 mg per day, or matching placebo for up to eight weeks (108 and 101 patients, respectively).

The researchers found that the mean unadjusted leg-pain intensity score was 3.7 in the pregabalin group and 3.1 in the placebo group at week eight (adjusted mean difference, 0.5; 95 percent confidence interval, −0.2 to 1.2; P = 0.19). The mean unadjusted leg-pain intensity score was 3.4 and 3.0 in the pregabalin and placebo groups, respectively, at week 52 (adjusted mean difference, 0.3; 95 percent confidence interval, −0.5 to 1.0; P = 0.46). There were no significant between-group differences for any secondary outcomes at week eight or 52. Overall, 227 and 124 adverse events were reported in the pregabalin and placebo groups, respectively.

"Treatment with pregabalin did not significantly reduce the intensity of leg pain associated with sciatica and did not significantly improve other outcomes, as compared with placebo, over the course of eight weeks," the authors write. "The incidence of adverse events was significantly higher in the pregabalin group than in the placebo group."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Osimertinib Tops Standard EGFR-TKI for EGFR NSCLC

Osimertinib Tops Standard EGFR-TKI for <i>EGFR</i>&#43; NSCLC

Significantly longer median progression-free survival for osimertinib in previously untreated NSCLC

Distinct Features for Drug Use-Related Endophthalmitis

Distinct Features for Drug Use-Related Endophthalmitis

Injection drug users have fewer comorbidities and more improvement in visual acuity after intervention

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Nonmedical use of prescription drugs linked to dating violence for male, female high school students

is free, fast, and customized just for you!

Already a member?

Sign In Now »